A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
BeOne Medicines
Bristol-Myers Squibb
Seagen Inc.
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca
Gilead Sciences
Hoffmann-La Roche
AstraZeneca
Thomas Jefferson University
Fudan University
Gilead Sciences
BeOne Medicines
Wake Forest University Health Sciences
TJ Biopharma Co., Ltd.
University Health Network, Toronto
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
CSPC Megalith Biopharmaceutical Co.,Ltd.
Mayo Clinic
Sun Yat-sen University
Weill Medical College of Cornell University
Bristol-Myers Squibb
Genfleet Therapeutics (Shanghai) Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Genelux Corporation
BeiGene
Mirati Therapeutics Inc.
University Hospital, Limoges
Iovance Biotherapeutics, Inc.
Ohio State University Comprehensive Cancer Center
Shanghai Chest Hospital
Fundación GECP
Merck Sharp & Dohme LLC
Tianjin Medical University Cancer Institute and Hospital
EpicentRx, Inc.
ImmunityBio, Inc.
Goethe University
AstraZeneca
Sichuan University
Hunan Province Tumor Hospital
Spanish Lung Cancer Group
Merck Sharp & Dohme LLC
Columbia University
BeBetter Med Inc
Tang-Du Hospital
Hunan Province Tumor Hospital
Canadian Cancer Trials Group
Liaoning Cancer Hospital & Institute